Cefodizime and cefotaxime in acute exacerbations of chronic bronchitis: a randomized double-blind prospective study in 180 patients

Maesen, F. P. V.; Davies, B. I.; Bergh, J. J. A. M. van den; Gubbelmans, H. L. L.; Meek, J. C. E.; Geraedts, Wiel

doi:10.1093/jac/25.3.413

Cited by 14 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…В большинстве зарубежных сравнительных исследо ваниях эффективности ЦС III поколения при инфекциях нижних дыхательных путей (ИНДП) была показана рав ная и высокая клиническая эффективность цефодизима, цефотаксима и цефтриаксона, составляющая от 78 до 99% с частотой микробной эрадикации от 71 до 98% [24][25][26][27][28].…”

Section: результаты клинических исследований эффективности и безопасн...unclassified

“…А в отдельном, имеющем наибольшую ценность, проспек тивном рандомизированном двойном слепом иссле довании у 180 пациентов с обострением хронической обструктивной болезни легких (ХОБЛ) клиническое из лечение в группах пациентов, принимавших цефодизим и цефотаксим в режиме 1 г два раза в день в течение 7 дней, составило впечатляющие 99 и 96% соответ ственно. При этом препараты сравнения назначались внутримышечно [25].…”

Section: результаты клинических исследований эффективности и безопасн...unclassified

See 1 more Smart Citation

Cefodizime: pharmacological characteristics and potential for clinical use in lower respiratory tract infections

Rachina,

Alkhlavov,

Gasanova

et al. 2023

CMAC

View full text Add to dashboard Cite

show abstract

Section: результаты клинических исследований эффективности и безопасн...unclassified

Cefodizime: pharmacological characteristics and potential for clinical use in lower respiratory tract infections

Rachina,

Alkhlavov,

Gasanova

et al. 2023

CMAC

View full text Add to dashboard Cite

show abstract

In vitro activity of cefodizime

Knothe

Shah

1992

Infection

View full text Add to dashboard Cite

Cefodizime is a bactericidal cephem with the typical broad spectrum activity of an aminothiazolyl cephalosporin, including both gram-positive and gram-negative bacteria: its MIC90 is 0.125 mg/l for Streptococcus pneumoniae, Streptococcus pyogenes and other streptococci; and 0.05 mg/l for Haemophilus spp., Neisseria meningitidis, Neisseria gonorrhoeae and Moraxella catarrhalis; while beta-lactamase positive strains of M. catarrhalis require 1 mg/l. Less than 1 mg/l is needed for Escherichia coli, Klebsiella spp., Proteus spp. and Shigella spp. The MIC90 is 4 mg/l for methicillin-sensitive Staphylococcus aureus, Morganella morganii, Providencia spp. and most strains of Serratia marcescens, Citrobacter spp. and Enterobacter spp. Staphylococcus epidermidis, Enterococcus faecalis and most strains of Pseudomonas spp. and Acinetobacter spp. are considered cefodizime-resistant. Cefodizime is unaffected by plasmid-mediated beta-lactamases, but it is hydrolyzed by some chromosomally mediated enzymes, thus resembling other third-generation cephalosporins. Cefodizime has high affinity for PBP 3 and PBP IA and IB (Escherichia coli); in S. aureus it shows the highest affinity for PBP 1.

show abstract

Clinical and bacteriological experience with cefodizime in acute purulent exacerbations of chronic bronchitis

et al. 1992

View full text Add to dashboard Cite

1 or 2 g doses of cefodizime i.m. were studied in 287 patients admitted to hospital with acute purulent exacerbations of chronic bronchitis, mostly associated with Haemophilus influenzae, Streptococcus pneumoniae or Moraxella catarrhalis. Pharmacokinetic studies in serum and sputum on the first treatment day yielded mean peak serum concentrations of 50 to 100 mg/l, with corresponding sputum concentrations of 1.4 and 2.7 mg/l, after the two respective doses. No great differences were found between the clinical and microbiological results in the various dosage groups, and no corresponding improvement was noted with the highest dosages studied. In general, infection was eliminated in 90 to 95% of patients at the end of treatment, and in approximately 70 to 80% after a follow-up week. Some infections associated with beta-lactamase producing M. catarrhalis persisted or relapsed after treatment. Unwanted drug effects were recorded in five patients, leading to discontinuation in two. It is concluded that a single daily intramuscular dose of 1 g cefodizime for seven days produces satisfactory results in most patients.

show abstract

Cefodizime and cefotaxime in acute exacerbations of chronic bronchitis: a randomized double-blind prospective study in 180 patients

Cited by 14 publications

References 0 publications

Cefodizime: pharmacological characteristics and potential for clinical use in lower respiratory tract infections

Cefodizime: pharmacological characteristics and potential for clinical use in lower respiratory tract infections

In vitro activity of cefodizime

Clinical and bacteriological experience with cefodizime in acute purulent exacerbations of chronic bronchitis

Contact Info

Product

Resources

About